Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CoQ10 in Huntington’s study

This article was originally published in The Tan Sheet

Executive Summary

The effect of coenzyme Q10 on cognitive function in Huntington's disease patients will be tested in a phase III clinical trial by the Huntington Study Group, according to a June 2 release. The five-year study will measure the maximum effective dosage of CoQ10 for treating Huntington's, a genetic, progressive brain disorder with no known cure or proven drug therapy. Pasadena, Texas-based Kaneka Nutrients will supply the supplement for the trial. In addition to its documented neurological benefits, CoQ10 has cardio health advantages pharmaceutical developers are attempting to harness (1"The Tan Sheet" June 2, 2008, p. 8)...

You may also be interested in...



Dietary Supplements Blossom As Revenue Growth Ingredients For Big Pharma

Dwindling product pipelines are pushing pharmaceutical companies to look to dietary supplements for business opportunities, not only through product sales but also by using herbal substances to develop new drug ingredients

Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders

Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.

Sandoz Pioneers Posaconazole And Silodosin In Canada

Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel